NU7441 (KU-57788)

Name: NU7441 (KU-57788)
Brand: Selleck Chemicals
SKU: S2638
Rating: 5 (103 reviews)

For research use only.

Catalog No.S2638

103 publications

Molecular Weight(MW): 413.49

NU7441 (KU-57788) is a highly potent and selective DNA-PK inhibitor with IC50 of 14 nM and also inhibits PI3K with IC50 of 5 μM in cell-free assays. It reduces the frequency of NHEJ while increasing the rate of HDR following Cas9-mediated DNA cleavage.

Selleck's NU7441 (KU-57788) has been cited by 103 publications

Nature, 2019, 74(7779):571-574

PubMed: 31645724 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2018, 34(3):396-410

PubMed: 30205044 ( click the link to review the publication )

Nat Biotechnol, 2017, 35(5):463-474

PubMed: 28319085 ( click the link to review the publication )

Nucleic Acids Res, 2020, 10.1093/nar/gkaa022

PubMed: 31965183 ( click the link to review the publication )

Sci Immunol, 2020, 5(43)

PubMed: 31980485 ( click the link to review the publication )

Nucleic Acids Res, 2020, 48(2):736-747

PubMed: 31740976 ( click the link to review the publication )

Oncotarget, 2020, 11(7):699-726

PubMed: 32133046 ( click the link to review the publication )

J Biol Chem, 2020, 295(1):125-137

PubMed: 31753920 ( click the link to review the publication )

Int J Mol Med, 2020, 45(6):1673-1684

PubMed: 32186748 ( click the link to review the publication )

Toxicol Lett, 2020, 318:104-113

PubMed: 31672611 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5304

PubMed: 31757956 ( click the link to review the publication )

Nat Commun, 2019, 10(1):1577

PubMed: 30952868 ( click the link to review the publication )

Nat Commun, 2019, 10(1):3925

PubMed: 31477700 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2866

PubMed: 31253785 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(18):5608-5622

PubMed: 31266829 ( click the link to review the publication )

Haematologica, 2019, 104(11):2225-2240

PubMed: 30819918 ( click the link to review the publication )

Int J Cancer, 2019, 10.1002/ijc.32558

PubMed: 31283004 ( click the link to review the publication )

Oncogene, 2019, 38(14):2451-2463

PubMed: 30532030 ( click the link to review the publication )

Cancers (Basel), 2019, 11(9)

PubMed: 31480356 ( click the link to review the publication )

Br J Cancer, 2019, 121(7):600-610

PubMed: 31481733 ( click the link to review the publication )

FASEB J, 2019, 33(11):11668-11681

PubMed: 31348687 ( click the link to review the publication )

FASEB J, 2019, 33(6):6778-6788

PubMed: 30807703 ( click the link to review the publication )
PLoS Genet, 2019, 15(2):e1007925

PubMed: 30716077 ( click the link to review the publication )

J Environ Manage, 2019, 244:77-82

PubMed: 31108313 ( click the link to review the publication )

Mol Cancer Res, 2019, 17(12):2457-2468

PubMed: 31551253 ( click the link to review the publication )

Toxicol Sci, 2019, 10.1093/toxsci/kfz178

PubMed: 31388677 ( click the link to review the publication )

J Biol Chem, 2019, 294(8):2827-2838

PubMed: 30598506 ( click the link to review the publication )

Retrovirology, 2019, 16(1):13

PubMed: 31036006 ( click the link to review the publication )

Front Physiol, 2019, 10:616

PubMed: 31178753 ( click the link to review the publication )

BMC Pulm Med, 2019, 19(1-:165

PubMed: 31464599 ( click the link to review the publication )

Mol Biol Rep, 2019, 10.1007/s11033-019-04605-0

PubMed: 31020489 ( click the link to review the publication )

Mol Biol Rep, 2019, 10.1007/s11033-019-05105-x

PubMed: 31583565 ( click the link to review the publication )

Mol Med Rep, 2019, 20(4):3609-3616

PubMed: 31485633 ( click the link to review the publication )

FEBS Open Bio, 2019, 9(7):1315-1326

PubMed: 31141305 ( click the link to review the publication )

Nucleic Acids Res, 2019, 47(21):10977-10993

PubMed: 31612207 ( click the link to review the publication )

Nucleic Acids Res, 2019, 47(18):9467-9479

PubMed: 31396623 ( click the link to review the publication )

Nucleic Acids Res, 2019, 47(16):8838-8859

PubMed: 31329944 ( click the link to review the publication )

Cell Res, 2018, 28(7):756-770

PubMed: 29844578 ( click the link to review the publication )

Nat Commun, 2018, 9(1):5351

PubMed: 30559436 ( click the link to review the publication )

Cell Rep, 2018, 24(4):987-1000

PubMed: 30044993 ( click the link to review the publication )

Cell Death Dis, 2018, 9(9):931

PubMed: 30209297 ( click the link to review the publication )

FASEB J, 2018, 32(4):1818-1829

PubMed: 29162700 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2551-2563

PubMed: 30217967 ( click the link to review the publication )

Hum Mol Genet, 2018, 27(23):4024-4035

PubMed: 30107443 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(3):428-438

PubMed: 29222170 ( click the link to review the publication )

DNA Repair (Amst), 2018, 68:68-74

PubMed: 30017059 ( click the link to review the publication )
Mol Biol Cell, 2018, 29(15):1786-1797

PubMed: 29897835 ( click the link to review the publication )

Sci Rep, 2018, 8(1):9685

PubMed: 29946146 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(10):5050-5060

PubMed: 29660033 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(17):8926-8939

PubMed: 30113698 ( click the link to review the publication )

Sci Rep, 2018, 8(1):14421

PubMed: 30258062 ( click the link to review the publication )

Biochem Biophys Rep, 2018, 16:115-121

PubMed: 30417129 ( click the link to review the publication )

Oncotarget, 2018, 9(9):8560-8572

PubMed: 29492217 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(1):244-254

PubMed: 28069995 ( click the link to review the publication )

Cancer Immunol Res, 2017, 5(9):790-803

PubMed: 28775208 ( click the link to review the publication )

Cancer Res, 2017, 77(17):4567-4578

PubMed: 28698210 ( click the link to review the publication )

Cancer Res, 2017, 77(18):4745-4754

PubMed: 28754673 ( click the link to review the publication )

J Cell Biol, 2017, 216(3):623-639

PubMed: 28228534 ( click the link to review the publication )

J Biol Chem, 2017, 292(30):12424-12435

PubMed: 28592488 ( click the link to review the publication )

Mol Biol Cell, 2017, 28(26):3756-3772

PubMed: 29074567 ( click the link to review the publication )

Int J Biochem Cell Biol, 2017, 92:164-172

PubMed: 28827033 ( click the link to review the publication )

Radiat Res, 2017, 188(6):597-604

PubMed: 28952912 ( click the link to review the publication )

PLoS One, 2017, 12(7):e0181608

PubMed: 28750002 ( click the link to review the publication )

DNA Repair (Amst), 2017, 54:30-39

PubMed: 28448822 ( click the link to review the publication )

Oncotarget, 2017, 8(52):90037-90049

PubMed: 29163809 ( click the link to review the publication )

Nat Cell Biol, 2016, 18(11):1196-1207

PubMed: 27723717 ( click the link to review the publication )

blood, 2016, 10.1182/blood-2016-02-700328

PubMed: ( click the link to review the publication )

Blood, 2016, 128(4):574-83

PubMed: 27235137 ( click the link to review the publication )

Nat Commun, 2016, 7:12880

PubMed: 27634057 ( click the link to review the publication )

Oncogene, 2016, 35(5):577-586

PubMed: 25893305 ( click the link to review the publication )
Cancer Lett, 2016, 383(1):41-52

PubMed: 27693461 ( click the link to review the publication )

Cell Death Dis, 2016, 7(7):e2316

PubMed: 27468692 ( click the link to review the publication )

Cell Cycle, 2016, 15(1):84-94

PubMed: 26771713 ( click the link to review the publication )

PLoS One, 2016, 11(12):e0167454

PubMed: 27907109 ( click the link to review the publication )

PLoS One, 2016, 11(5):e0155230

PubMed: 27153109 ( click the link to review the publication )

PLoS One, 2016, 11(9):e0163049

PubMed: 27643854 ( click the link to review the publication )

Nucleic Acids Res, 2016, 44(11):5204-17

PubMed: 27001513 ( click the link to review the publication )

Oncotarget, 2016, 7(38):60807-60822

PubMed: 27602502 ( click the link to review the publication )

Nucleic Acids Res, 2016, 44(8):3695-712

PubMed: 26843428 ( click the link to review the publication )

Oncotarget, 2016, 7(40):65504-65513

PubMed: 27602767 ( click the link to review the publication )

Nat Cell Biol, 2015, 17(9):1158-68

PubMed: 26237645 ( click the link to review the publication )

Leukemia, 2015, 29(5):1133-42

PubMed: 25371178 ( click the link to review the publication )

Genome Med, 2015, 10.1186/s13073-015-0215-6

PubMed: 26307031 ( click the link to review the publication )

Mol Cancer Res, 2015, 13(1):120-9

PubMed: ( click the link to review the publication )

Mol Cancer Res, 2015, 13(1):120-9

PubMed: 25232030 ( click the link to review the publication )

Cancer Biol Ther, 2015, 16(11):1585-92

PubMed: 26382920 ( click the link to review the publication )

Anticancer Res, 2015, 35(7):3829-38

PubMed: 26124328 ( click the link to review the publication )

Nucleic Acids Res, 2014, 42(12):7776-92

PubMed: 24906880 ( click the link to review the publication )

Nucleic Acids Res, 2014, 42(9):5616-32

PubMed: 24598253 ( click the link to review the publication )

Genes Dev, 2014, 28(8):875-87

PubMed: 24700029 ( click the link to review the publication )

Cancer Res, 2014, 74(16):4282-94

PubMed: 24894717 ( click the link to review the publication )

Oncogene, 2014, 10.1038/onc.2014.268

PubMed: 25132265 ( click the link to review the publication )

ACS Chem Biol, 2014, 9(5):1160-71

PubMed: 24568369 ( click the link to review the publication )

Toxicol Sci, 2014, 10.1093/toxsci/kfu207

PubMed: 25288669 ( click the link to review the publication )
Biosci Rep, 2014, 34(3)

PubMed: 24844881 ( click the link to review the publication )

Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, 2014,

PubMed: ( click the link to review the publication )

Uppsala University, 2014, Department of Radiology

PubMed: ( click the link to review the publication )

Nucleic Acids Res, 2013, 41(22):10157-69

PubMed: 24021630 ( click the link to review the publication )

Nucleic Acids Res, 2013, 41(7):4080-92

PubMed: 23449221 ( click the link to review the publication )

Nucleic Acids Res, 2013, 41(15):7378-86

PubMed: 23775790 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2013, 88(2):385-94

PubMed: 24411611 ( click the link to review the publication )

Purity & Quality Control

Choose Selective DNA-PK Inhibitors

Biological Activity

Description

Targets

DNA-PK ^[1]
(Cell-free assay)

14 nM

In vitro

NU7441 increases the persistence of γH2AX foci after ionizing radiation–induced or etoposide-induced DNA damage. NU7441 (0.5 μM or 1 μM) appreciably increases G2-M accumulation induced by ionizing radiation, etoposide, and doxorubicin in both SW620 and LoVo cells. ^[2] NU7441 causes persistence of doxorubicin- and ionising radiation-induced DNA double-strand break and also slightly decreases homologous recombination activity DNA-PK-proficient M059-Fus-1 and DNA-PK-deficient M059 J human tumour cells. ^[3] NU7441 inhibits UV-induced RPA p34 hyperphosphorylation in a dose-dependent manner both in cells lacking and cells expressing polymerase η. ^[4] NU7441 increases levels of fludarabine-induced γH2AX foci and correspondingly decreased fludarabine-induced cell death in chronic lymphocytic leukemia cells. ^[5] NU7441 also inhibits mitoxantrone-induced DNA-PKcs autophosphorylation and repair in chronic lymphocytic leukemia cells. ^[6] It reduces the frequency of NHEJ while increasing the rate of HDR following Cas9-mediated DNA cleavage^[7].

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
NCI-H1770	NIrMZpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGDibFJKSzVyPUCuNFIyPDNizszN	MYHTRW5ITVJ?
A172	NYC2UHA4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUHJR\|UxRTBwMUWzNVYh\|ryP	MYTTRW5ITVJ?
NCI-H526	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4LOTGlEPTB;MD6yPFQxPyEQvF2=	MWPTRW5ITVJ?
HDLM-2	M2fEUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M13zfmlEPTB;MD6zNlM1PSEQvF2=	NUfqNZlxW0GQR1XS
HuO-3N1	NFHoZZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlrGTWM2OD1yLkS2OlM3KM7:TR?=	MkW1V2FPT0WU
NCI-SNU-1	MmrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoG3TWM2OD1yLk[wPVk1KM7:TR?=	M3vPcnNCVkeHUh?=
SK-N-AS	MkjMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2\SZ2lEPTB;MD62NlIyPiEQvF2=	MYTTRW5ITVJ?
LoVo	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkDQTWM2OD1yLki2O\|Q6KM7:TR?=	MlrPV2FPT0WU
LAMA-84	M3Hud2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{fwfGlEPTB;MD65PFg{OyEQvF2=	NXWzTll1W0GQR1XS
CTB-1	M4jpZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4m3[2lEPTB;MT6xNVU1PiEQvF2=	NHr0V3dUSU6JRWK=
KP-N-YS	M2jocWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4fLWmlEPTB;MT6xOFI{OSEQvF2=	MoDxV2FPT0WU
HH	NH7GXHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnzvTWM2OD1zLkG4NFk{KM7:TR?=	MYfTRW5ITVJ?
CHL-1	NEXqZnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4[4cmlEPTB;MT6yNVM3QCEQvF2=	Mkn5V2FPT0WU
NB7	M{XWe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIraXHRKSzVyPUGuNlQ4PDVizszN	NEnid3VUSU6JRWK=
HL-60	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MU\JR\|UxRTFwM{ixPUDPxE1?	NFXHOmhUSU6JRWK=
639-V	NGrmdpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEnNOmxKSzVyPUGuOFQyOjhizszN	MlHDV2FPT0WU
NCI-H1793	NFHaRXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1TaXmlEPTB;MT60OVg1KM7:TR?=	MmqyV2FPT0WU
NEC8	M2i0eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1\ObmlEPTB;MT61OVM2KM7:TR?=	MUjTRW5ITVJ?
PA-1	M2rRdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVzJR\|UxRTFwNUiyPVQh\|ryP	MorNV2FPT0WU
D-423MG	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn;tTWM2OD1zLk[5N\|YyKM7:TR?=	NELQS5BUSU6JRWK=
NCI-H292	M3nUbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4rZNmlEPTB;MT63OFAyOyEQvF2=	MmPOV2FPT0WU
SK-MEL-1	MlHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4L3bmlEPTB;MT63PVQ4QSEQvF2=	MnnpV2FPT0WU
LB2241-RCC	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4nUSmlEPTB;Mj6xOFE1PiEQvF2=	MmLVV2FPT0WU
SK-MEL-3	NYrQeJVQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVrJR\|UxRTJwMU[0PUDPxE1?	NUnKXlMzW0GQR1XS
MHH-PREB-1	NInJN\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnvjTWM2OD1{LkG2OlA6KM7:TR?=	NG\HNFRUSU6JRWK=
BFTC-905	Mlm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHXafnVKSzVyPUKuNVY3QDdizszN	MYXTRW5ITVJ?
Ramos-2G6-4C10	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkPsTWM2OD1{LkG5PVA6KM7:TR?=	NHu1[5dUSU6JRWK=
G-361	M33qUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWPYOHBKUUN3ME2yMlIyPjhizszN	MXLTRW5ITVJ?
MOLT-4	NXW0U5RwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVryNW1CUUN3ME2yMlIyQDh6IN88US=>	NWDFbVlsW0GQR1XS
DEL	NGG4fGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHfVfYVKSzVyPUKuN\|U2PjRizszN	NI[3WJJUSU6JRWK=
MV-4-11	NWDKWGNIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWjJR\|UxRTJwM{ezPUDPxE1?	MoW2V2FPT0WU
SK-NEP-1	M1ntV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXzsU3k1UUN3ME2yMlM5Pzh\|IN88US=>	M1TKeHNCVkeHUh?=
RS4-11	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnXjTWM2OD1{LkW2NFI{KM7:TR?=	NVjpfnptW0GQR1XS
HuH-7	M3PNNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWD4Z5BzUUN3ME2yMlU3PzB{IN88US=>	NEXiT5BUSU6JRWK=
A101D	NFy5ZZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2HRTGlEPTB;Mj62NVM{QCEQvF2=	MnHGV2FPT0WU
KG-1	NVPVTGt3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEfDOWZKSzVyPUKuOlc6OjRizszN	NYHYbm9{W0GQR1XS
KALS-1	NYCx[GtLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmH5TWM2OD1{Lk[5OlM{KM7:TR?=	NWHLfotjW0GQR1XS
VMRC-RCZ	NIHiUXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHn4OJZKSzVyPUKuO\|c{OjhizszN	MY\TRW5ITVJ?
SK-UT-1	MnHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{LFSGlEPTB;Mz6xOVMyKM7:TR?=	MnG1V2FPT0WU
SW962	NVKybZFuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml:wTWM2OD1\|LkKwN\|UzKM7:TR?=	MlnlV2FPT0WU
DBTRG-05MG	M2m5fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3\E[2lEPTB;Mz6yPFA5PSEQvF2=	M3O3SXNCVkeHUh?=
PANC-08-13	MlP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmH2TWM2OD1\|LkSxNlc5KM7:TR?=	NHjZPJFUSU6JRWK=
QIMR-WIL	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2\ZXGlEPTB;Mz60NVM1OSEQvF2=	NFPSNXBUSU6JRWK=
SK-MEL-30	M1PiN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHPvXllKSzVyPUOuOFI2QThizszN	MU\TRW5ITVJ?
697	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlmwTWM2OD1\|LkS0PVk{KM7:TR?=	M2njSHNCVkeHUh?=
NY	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXrIe4tKUUN3ME2zMlQ2ODJ{IN88US=>	MYXTRW5ITVJ?
ES7	M2TObWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1WweGlEPTB;Mz60OlczQSEQvF2=	MlWzV2FPT0WU
JVM-3	NVPRVlRWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2jMZmlEPTB;Mz60PFA4PyEQvF2=	MmPjV2FPT0WU
U031	NYHnelZYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mlu0TWM2OD1\|LkW5N\|Y5KM7:TR?=	NXrzTnVOW0GQR1XS
BHT-101	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVPtO3I{UUN3ME2zMlU6QTh3IN88US=>	NXrUN\|l5W0GQR1XS
8305C	NYS5WGJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NILPV2dKSzVyPUOuOlE4OzZizszN	NFXM[ZdUSU6JRWK=
MG-63	NHHV[2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVnJR\|UxRTNwNkK2O\|Yh\|ryP	M2TwTHNCVkeHUh?=
NOS-1	NVr5SZI5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2\0N2lEPTB;Mz62OVMyOiEQvF2=	M3LnTXNCVkeHUh?=
YH-13	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX7JR\|UxRTNwOEexPFkh\|ryP	NHfpbItUSU6JRWK=
LXF-289	NHKzb4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmfkTWM2OD1\|LkmxNFQyKM7:TR?=	NUTyVmRNW0GQR1XS
GOTO	NEHUXpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NW\EblJvUUN3ME2zMlkyPDlizszN	MWHTRW5ITVJ?
EKVX	MlTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYTaSnp1UUN3ME20MlIzPTJ2IN88US=>	MX7TRW5ITVJ?
CAL-51	MnX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3\icmlEPTB;ND6yOFg2PCEQvF2=	MXLTRW5ITVJ?
AN3-CA	MnjQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIrne3hKSzVyPUSuNlU5OTNizszN	NXT5XGxRW0GQR1XS
IA-LM	NHTDWWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXnCR5lNUUN3ME20MlI4QTN3IN88US=>	M2X2WXNCVkeHUh?=
KU-19-19	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUDWSZNVUUN3ME20MlMzQTJzIN88US=>	NIjHU\|RUSU6JRWK=
A704	M1zVS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MULJR\|UxRTRwNEC4PFgh\|ryP	MYLTRW5ITVJ?
RH-18	Mlz0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYjpOFhqUUN3ME20MlQ1QTV\|IN88US=>	Mn7EV2FPT0WU
IST-MEL1	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYfDdINJUUN3ME20MlU5OjZ\|IN88US=>	NXr2TFZRW0GQR1XS
LU-134-A	NF;xZZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXy5ToFqUUN3ME20MlU6Pjh3IN88US=>	MkPyV2FPT0WU
SF126	NFjxboJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXrUNmJIUUN3ME20MlYxPzF3IN88US=>	MVXTRW5ITVJ?
EFO-27	M{\UXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MonoTWM2OD12Lk[2OVI2KM7:TR?=	NVLuWnVPW0GQR1XS
SN12C	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnvuTWM2OD12LkexPFk5KM7:TR?=	M{DnZnNCVkeHUh?=
L-363	NV3YNnhNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3nzVmlEPTB;ND63O\|EyPiEQvF2=	NIra[49USU6JRWK=
MEL-HO	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1qxd2lEPTB;ND63O\|k5QSEQvF2=	MVTTRW5ITVJ?
TYK-nu	M1\5NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHr5Ro1KSzVyPUSuPFAyOjhizszN	NVTz[mUyW0GQR1XS
MDA-MB-415	M{fPemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4HITGlEPTB;NT6wNFMyPCEQvF2=	MVTTRW5ITVJ?
HCC70	M3zHbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkjlTWM2OD13LkCzPVM6KM7:TR?=	MlvuV2FPT0WU
IGROV-1	M3nXXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnL5TWM2OD13LkK1NlkzKM7:TR?=	M2S3U3NCVkeHUh?=
NCI-H1355	NUfNd\|Y{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2\xe2lEPTB;NT6yPVYh\|ryP	MU\TRW5ITVJ?
23132-87	NIXTe2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWPEdmdIUUN3ME21MlMzODJ2IN88US=>	M{SzXHNCVkeHUh?=
NB69	NXzkNVNtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoDXTWM2OD13LkOyOFIh\|ryP	M4Tke3NCVkeHUh?=
HSC-2	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2fsT2lEPTB;NT60NVc4OyEQvF2=	M3LER3NCVkeHUh?=
KYSE-410	MmL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX;KVpNQUUN3ME21MlQ4PjN4IN88US=>	MoDEV2FPT0WU
GCIY	NVe4NXUyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEj2XHdKSzVyPUWuOVE{PzhizszN	MlzoV2FPT0WU
A427	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYrJR\|UxRTVwNUO2OlEh\|ryP	MWLTRW5ITVJ?
ChaGo-K-1	M2SyOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXTJR\|UxRTVwNU[1PVkh\|ryP	Mnm2V2FPT0WU
PFSK-1	Ml64S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml7nTWM2OD13Lk[yNVk1KM7:TR?=	M4TkbXNCVkeHUh?=
MLMA	NILTbldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF\mVnBKSzVyPUWuPFM3ODZizszN	NWnsZ2JPW0GQR1XS
RVH-421	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF\LPYFKSzVyPU[uNFc{OzhizszN	MVjTRW5ITVJ?
LB1047-RCC	MmTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX;JR\|UxRTZwMUe1NlIh\|ryP	NYfiU2dTW0GQR1XS
MHH-NB-11	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml7LTWM2OD14LkOyO\|IyKM7:TR?=	NYXNZlJ7W0GQR1XS
J-RT3-T3-5	MmriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4HsTGlEPTB;Nj62N\|I6OSEQvF2=	NEHIWHZUSU6JRWK=
UM-UC-3	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXHrboxqUUN3ME22MlY1OzN2IN88US=>	M1;zU3NCVkeHUh?=
IST-SL1	NWD2PJR{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUHJR\|UxRTZwNkmzOlkh\|ryP	NYX2PVJSW0GQR1XS
NB14	NFm2VXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml;YTWM2OD14Lke5O\|YyKM7:TR?=	MU\TRW5ITVJ?
NBsusSR	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHPjbGtKSzVyPU[uPFI2ODJizszN	MXrTRW5ITVJ?
D-263MG	Mnq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn\wTWM2OD14LkmxNFY5KM7:TR?=	MXTTRW5ITVJ?
NCI-H2347	Ml\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{n6R2lEPTB;Nj65N\|IyOyEQvF2=	MXHTRW5ITVJ?
ES8	Mm[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{S2XGlEPTB;Nj65O\|U5QCEQvF2=	M4nab3NCVkeHUh?=
786-0	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1nsUWlEPTB;Nz6wPVc5PiEQvF2=	MWTTRW5ITVJ?
EPLC-272H	MnTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX3vTXV5UUN3ME23MlE3OjR4IN88US=>	MVzTRW5ITVJ?
CAPAN-1	MmTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX7JR\|UxRTdwMkSzOVkh\|ryP	NVLEdXdsW0GQR1XS
NCI-H82	MnHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4T0U2lEPTB;Nz6yOlY2QSEQvF2=	Mn63V2FPT0WU
G-402	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEXZbopKSzVyPUeuN\|AxPTFizszN	MlrYV2FPT0WU
SW982	NEXvdYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVTrR\|FGUUN3ME23MlMxOjB\|IN88US=>	MV3TRW5ITVJ?
OVCAR-4	MnztS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmjsTWM2OD15LkOxN\|I5KM7:TR?=	MYDTRW5ITVJ?
KARPAS-299	MlTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoO1TWM2OD15LkOyOlIzKM7:TR?=	MV3TRW5ITVJ?
MIA-PaCa-2	Ml\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWnJR\|UxRTdwM{[4NlMh\|ryP	NHLOemZUSU6JRWK=
AU565	MlT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEflT2FKSzVyPUeuOVk5OzNizszN	NFPSTGNUSU6JRWK=
GAMG	NEXMT\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1LiXWlEPTB;Nz62OFE{OSEQvF2=	MlXxV2FPT0WU
HuO9	NFvre4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3PDV2lEPTB;Nz63NVc1OyEQvF2=	MnfTV2FPT0WU
ACN	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnHSTWM2OD15Lke0N\|Mh\|ryP	MUXTRW5ITVJ?
RO82-W-1	NUXlOok1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUnJR\|UxRTdwN{S1N\|Mh\|ryP	NULCR\|V3W0GQR1XS
NKM-1	M1frU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV;nRo4zUUN3ME23Mlc1QTV3IN88US=>	NFr6[4ZUSU6JRWK=
CAL-12T	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVTseWdYUUN3ME23Mlk1OzV{IN88US=>	NXzzUGl1W0GQR1XS
FADU	M1Tne2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MULJR\|UxRThwMEO2OVQh\|ryP	Mk\mV2FPT0WU
NCI-H28	Mn30S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3jTc2lEPTB;OD6xOlk3OiEQvF2=	NI\QS3BUSU6JRWK=
LCLC-97TM1	NHzqfIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NELWTpJKSzVyPUiuNlEyOjJizszN	M3\VW3NCVkeHUh?=
CHP-134	NWHGbIJWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3\qfWlEPTB;OD6yOFE5PSEQvF2=	M3;0THNCVkeHUh?=
HT-1080	NVeyZm9uT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M37QSmlEPTB;OD6yOVA6OyEQvF2=	MXzTRW5ITVJ?
PC-3	MlLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmL3TWM2OD16LkK3N\|kzKM7:TR?=	MVTTRW5ITVJ?
SNU-449	NHrCS3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXHTdpFTUUN3ME24MlI4QTNizszN	NUG1TGtVW0GQR1XS
VA-ES-BJ	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF\BdXNKSzVyPUiuN\|Q3QDZizszN	NFy5TIFUSU6JRWK=
HT	NXv2R3hNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF\kNoRKSzVyPUiuN\|Y1QSEQvF2=	NEPJPFVUSU6JRWK=
HOS	M{S3OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFv0WJRKSzVyPUiuN\|c2QDlizszN	NXjqdZFWW0GQR1XS
KNS-62	M1jwTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWnxXVV3UUN3ME24MlM4PzZ{IN88US=>	NF3LZYJUSU6JRWK=
OAW-42	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXrFRo9qUUN3ME24Mlk2QTZ2IN88US=>	NIr6U4FUSU6JRWK=
A549	M2XD[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1Lwb2lEPTB;OT6wPVYyOiEQvF2=	M3\MenNCVkeHUh?=
CAKI-1	NYqwOmxVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV\JR\|UxRTlwMU[2NUDPxE1?	NHXGeIVUSU6JRWK=
HCC1937	NIDpZmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV\JR\|UxRTlwNkm4OlUh\|ryP	NFPKcXdUSU6JRWK=
GI-ME-N	M{Tydmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIe0fVhKSzVyPUmuO\|AyOzdizszN	M3n1[HNCVkeHUh?=
DU-4475	NIG3fW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVnFc49mUUN3ME25Mlk3QTN7IN88US=>	M{LZVXNCVkeHUh?=
EM-2	M{DUfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUPJR\|UxRTFyLkK0NlYh\|ryP	MnHRV2FPT0WU
NCI-H1755	Ml3qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGHncXpKSzVyPUGwMlI1OjhizszN	MYfTRW5ITVJ?
NCI-H1437	MmLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUfJXG1UUUN3ME2xNE42PzJ3IN88US=>	NFrXN\|lUSU6JRWK=
VM-CUB-1	MorRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF3RUJVKSzVyPUGwMlYyPjRizszN	MX3TRW5ITVJ?
A2058	NEfBUolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnfBTWM2OD1zMD62OFA1KM7:TR?=	NVHyXHBpW0GQR1XS
BPH-1	M3SyXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4DFZ2lEPTB;MUCuO\|E1PSEQvF2=	NXrFdI41W0GQR1XS
NB5	NWnse3NHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4Lo[WlEPTB;MUCuO\|U2QSEQvF2=	NFHYNotUSU6JRWK=
G-401	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NImwfXdKSzVyPUGwMlc3OjZizszN	NW\JSZhTW0GQR1XS
CAL-72	NHnGboNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHrwVYRKSzVyPUGwMlgxQTRizszN	NX\PNIdZW0GQR1XS
SK-MEL-28	NH62VZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXzvZY02UUN3ME2xNE45OjB{IN88US=>	M{jvT3NCVkeHUh?=
C32	NEfXZ\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUHJR\|UxRTFyLkizOFch\|ryP	Mn7IV2FPT0WU
NCI-H1155	M{PBNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWXJR\|UxRTFyLkizO\|Yh\|ryP	NETx[pZUSU6JRWK=
BB49-HNC	NFj6XWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnvyTWM2OD1zMD64OVg3KM7:TR?=	NV21b4oyW0GQR1XS
GMS-10	NET5bJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1jvVmlEPTB;MUCuPFk4OSEQvF2=	NUfRN\|U{W0GQR1XS
K5	M1fUT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFLFWFhKSzVyPUGwMlkxPzFizszN	MVTTRW5ITVJ?
OS-RC-2	NH3VPFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4jvfWlEPTB;MUGuNFU2QSEQvF2=	NFHOdY1USU6JRWK=
HTC-C3	M1qyWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2T6WmlEPTB;MUGuNFcyPCEQvF2=	NHfWZpFUSU6JRWK=
LB996-RCC	M2XvOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUThbm1FUUN3ME2xNU4xPzJ\|IN88US=>	M{LUXnNCVkeHUh?=
NCI-H1563	M{XXVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUnlOFdHUUN3ME2xNU4yODFzIN88US=>	M1PkXHNCVkeHUh?=
CAL-54	NV3PVGdQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUO5fXExUUN3ME2xNU41QDFzIN88US=>	Mn\hV2FPT0WU
WM-115	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3HDOWlEPTB;MUGuOlgzPCEQvF2=	MoHSV2FPT0WU
COLO-684	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MY\JR\|UxRTFzLkeyOlch\|ryP	NH:5T\|VUSU6JRWK=
HOP-62	M3n2Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIL2WHBKSzVyPUGxMlc2ODhizszN	NYXWdHZ7W0GQR1XS
NCI-H650	M4X4dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFjEWGpKSzVyPUGxMlg6PjFizszN	NHPrclVUSU6JRWK=
TE-11	M4jMfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGWwbW1KSzVyPUGxMlk{OTVizszN	MX;TRW5ITVJ?
COLO-679	NE\TXnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWPvT5BRUUN3ME2xNU46PDZizszN	MojsV2FPT0WU
FTC-133	NWK4cmZPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlrHTWM2OD1zMj6wNFc3KM7:TR?=	MnTNV2FPT0WU
D-283MED	MkPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXK1WJBtUUN3ME2xNk4xPTZ7IN88US=>	NGXrZ45USU6JRWK=
SK-PN-DW	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3HMTmlEPTB;MUKuNVkxOiEQvF2=	NGDCZ41USU6JRWK=
BALL-1	MoLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkHwTWM2OD1zMj6yOlYzKM7:TR?=	MV7TRW5ITVJ?
GT3TKB	M{TtcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVXJR\|UxRTF{LkOwO\|Qh\|ryP	MXnTRW5ITVJ?
HOP-92	NFyxbGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVXJR\|UxRTF{LkWyN\|Mh\|ryP	M{Dm[HNCVkeHUh?=
M14	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX\JR\|UxRTF\|LkCzN\|Uh\|ryP	MoHnV2FPT0WU
SKG-IIIa	NIXkdGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV\FVoZPUUN3ME2xN{4xPTV2IN88US=>	NX\Jbmw3W0GQR1XS
Becker	NX\wWHp3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV74OWViUUN3ME2xN{4xPThizszN	MV\TRW5ITVJ?
ES5	MkfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHq3cVVKSzVyPUGzMlE{PTZizszN	M4rtNnNCVkeHUh?=
NCI-H2030	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWfVenlIUUN3ME2xN{4zODZ{IN88US=>	M4\6eXNCVkeHUh?=
SNU-423	NHjy[W9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3fySWlEPTB;MUOuN\|gyKM7:TR?=	NI[5ZohUSU6JRWK=
CP50-MEL-B	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1zSemlEPTB;MUOuOlI{OiEQvF2=	MWLTRW5ITVJ?
NCI-H1092	NIfZUZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH\6enNKSzVyPUGzMlc1PzVizszN	MknlV2FPT0WU
8-MG-BA	Mnf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn3TTWM2OD1zMz63OVE{KM7:TR?=	MVnTRW5ITVJ?
CAL-27	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MY\JR\|UxRTF2LkC3Nlch\|ryP	M136SHNCVkeHUh?=
AGS	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYXnWIdUUUN3ME2xOE4yOzF7IN88US=>	NHTmdnNUSU6JRWK=
MZ2-MEL	NF;VWVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmnoTWM2OD1zND6xOFg5KM7:TR?=	M3XDR3NCVkeHUh?=
BFTC-909	NFLBWYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWfJR\|UxRTF2LkWwOVUh\|ryP	MnfFV2FPT0WU
D-566MG	NGfZeIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnHHTWM2OD1zND63O\|A3KM7:TR?=	M4fpOnNCVkeHUh?=
MZ7-mel	NGf4[4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NITvTW5KSzVyPUG1MlExPjdizszN	NH\FO3pUSU6JRWK=
TE-5	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn7sTWM2OD1zNT6yN\|M{KM7:TR?=	MV3TRW5ITVJ?
647-V	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYrJR\|UxRTF3LkK3NFUh\|ryP	M172eHNCVkeHUh?=
DMS-114	M2TP[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4nKdGlEPTB;MUWuN\|I6OSEQvF2=	MkO3V2FPT0WU
ME-180	NWK0SJY1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVKwT4ZyUUN3ME2xOU41Pzh\|IN88US=>	MXfTRW5ITVJ?
MS-1	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmrsTWM2OD1zNT61OlI{KM7:TR?=	NX\0foZNW0GQR1XS
NUGC-3	M1:0V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4nWdGlEPTB;MUWuOlI1PSEQvF2=	NV7aZZpWW0GQR1XS
GB-1	M3\scmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX\5RXhpUUN3ME2xOU43PDN5IN88US=>	MnmyV2FPT0WU
LOXIMVI	NYmyfXVQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHjnSoNKSzVyPUG1Mlg6OTlizszN	NGmwbZpUSU6JRWK=
NCI-H1304	NGHWXGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWfzRnplUUN3ME2xOU45QTJ6IN88US=>	NGn2SI1USU6JRWK=
KURAMOCHI	NFTaVnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUfJR\|UxRTF3Lkm3NUDPxE1?	NH;xPHdUSU6JRWK=
SW1783	NYPtUFUyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF;COoZKSzVyPUG2MlA6QTNizszN	MXfTRW5ITVJ?
EGI-1	NIDYOZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXTJR\|UxRTF4LkWzOlUh\|ryP	MoPrV2FPT0WU
KGN	NUjtcGtRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mm\CTWM2OD1zNj61OVg3KM7:TR?=	M4TSTHNCVkeHUh?=
PANC-03-27	M3\nUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHfzeIJKSzVyPUG2Mlc3PjJizszN	NIrh[lBUSU6JRWK=
RH-1	M3PYW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYfsbIZ7UUN3ME2xOk45OjVizszN	Mo\wV2FPT0WU
HT-1376	M4qydGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVTJR\|UxRTF4Lki0OFYh\|ryP	NInrdJdUSU6JRWK=
ZR-75-30	NW[zRmkxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIrVc49KSzVyPUG2Mlk{PjFizszN	M3ixXHNCVkeHUh?=
TI-73	M4jQSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYrJR\|UxRTF4Lkm0NFgh\|ryP	NXnUO2Q4W0GQR1XS
TK10	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn30TWM2OD1zNz6wNFc6KM7:TR?=	NXPWWItMW0GQR1XS
SW684	M1G2XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3LTSWlEPTB;MUeuNFE2PCEQvF2=	NUXGTZhOW0GQR1XS
RPMI-8866	NHLnWWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIPadYxKSzVyPUG3MlA3QTlizszN	NGHFWWVUSU6JRWK=
LNCaP-Clone-FGC	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVjJR\|UxRTF5LkWyNFEh\|ryP	MmnVV2FPT0WU
NCI-H2291	NHu3WZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEHwNo5KSzVyPUG4MlQ{PDVizszN	MkLSV2FPT0WU
T47D	M2Pwfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWnJR\|UxRTF6LkS4PEDPxE1?	NX76Z491W0GQR1XS
A204	NIHBSIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYPZeHFuUUN3ME2xPE42PDV{IN88US=>	NIDZenNUSU6JRWK=
HT-144	NWDj[2E2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUH1RWVvUUN3ME2xPE44PDJ5IN88US=>	NIfEdWxUSU6JRWK=
MDA-MB-361	NHvUV5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVfsT5lDUUN3ME2xPU4xPzF2IN88US=>	M2r0PHNCVkeHUh?=
HCC1806	MkT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFHncVlKSzVyPUG5MlE2QTFizszN	M{HxfXNCVkeHUh?=
NCI-H596	NGq5PWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnPuTWM2OD1zOT62N\|kyKM7:TR?=	M3zEWnNCVkeHUh?=
K-562	Ml3DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml3wTWM2OD1zOT64PVI3KM7:TR?=	M{f4WnNCVkeHUh?=
D-336MG	MkXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4n6RmlEPTB;MUmuPVMzOiEQvF2=	NUTGenZ6W0GQR1XS
SK-MEL-2	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGnUNXJKSzVyPUKwMlE2PTlizszN	MlfzV2FPT0WU
HEC-1	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2ThbmlEPTB;MkCuOFk4QCEQvF2=	M{n3WHNCVkeHUh?=
EW-13	NH73Z3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH;K[nVKSzVyPUKwMlU1PDNizszN	M2DwbHNCVkeHUh?=
Hs-578-T	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3f4PGlEPTB;MkCuOVU5OyEQvF2=	MYLTRW5ITVJ?
SJSA-1	NIPyRXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1PmWWlEPTB;MkCuOVY5QCEQvF2=	MkK3V2FPT0WU
RCC10RGB	M{SxcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYDCN45sUUN3ME2yNE43PzF7IN88US=>	M1O0VXNCVkeHUh?=
LAN-6	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MULJR\|UxRTJzLkCzPVYh\|ryP	MW\TRW5ITVJ?
NCI-H1048	NXTXb3A5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXjTSnQ{UUN3ME2yNU4zOjV6IN88US=>	MYLTRW5ITVJ?
CW-2	Mn;WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFjKVlBKSzVyPUKxMlI4ODVizszN	NV7iV5E2W0GQR1XS
HCC2157	M1PUOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWXJR\|UxRTJzLkO2JO69VQ>?	NGniSZRUSU6JRWK=
EW-22	NGXwZnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUC2Z3E4UUN3ME2yNU4{PzZizszN	M1Ln[nNCVkeHUh?=
A253	MkPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXfJR\|UxRTJzLkS0PFEh\|ryP	M1PuVnNCVkeHUh?=
BE-13	NH;LU4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{P2dmlEPTB;MkGuOlEyOyEQvF2=	M13aV3NCVkeHUh?=
KINGS-1	NHrUZldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MW\JR\|UxRTJzLk[zNVYh\|ryP	MmjJV2FPT0WU
ETK-1	M{W2fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmLQTWM2OD1{MT64NVUzKM7:TR?=	M2myZnNCVkeHUh?=
NCI-H2452	M1ez[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXj0TokxUUN3ME2yNU45PjR5IN88US=>	NWWwO\|hsW0GQR1XS
HPAF-II	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXTLSYF[UUN3ME2yNU45QTJ\|IN88US=>	MlL1V2FPT0WU
D-542MG	MljJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXvJR\|UxRTJzLkmwOlkh\|ryP	NHGyUIdUSU6JRWK=
NCI-H630	M3;lcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVTJR\|UxRTJ{LkCyPVYh\|ryP	NWToVVFVW0GQR1XS
TGBC11TKB	MnT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlX2TWM2OD1{Mj6wOFkh\|ryP	NGPUbZJUSU6JRWK=
BCPAP	MkXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX7RPIZ2UUN3ME2yNk43OTFizszN	MmnXV2FPT0WU
HLE	MoHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEPoRnVKSzVyPUKyMlY6PyEQvF2=	M2\WdHNCVkeHUh?=
NCI-H727	NUHkPXdHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NI\kNlBKSzVyPUKyMlc{PSEQvF2=	NXLUNI1jW0GQR1XS
RD	M1Xsbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVHJR\|UxRTJ{Lke1NVgh\|ryP	MnvhV2FPT0WU
NCI-H522	M{nkO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVfpclZKUUN3ME2yNk45PDNzIN88US=>	MVLTRW5ITVJ?
CGTH-W-1	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUjXXHJ{UUN3ME2yN{4xPjRzIN88US=>	MYnTRW5ITVJ?
SK-LU-1	NF7PVYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlXBTWM2OD1{Mz60Olg{KM7:TR?=	NYPHWFhlW0GQR1XS
BB65-RCC	NGrqbXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUHGToJ3UUN3ME2yN{44QDZ\|IN88US=>	NVfre4dmW0GQR1XS
HSC-3	Mmi3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHW5SWRKSzVyPUKzMlg2OjdizszN	MVnTRW5ITVJ?
SK-MES-1	MoHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUPJR\|UxRTJ2LkCxOlEh\|ryP	NWD4[FBFW0GQR1XS
DB	NGrSSHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkXYTWM2OD1{ND6xNFI5KM7:TR?=	M1TP[HNCVkeHUh?=
HO-1-N-1	Mof2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXLLN\|RlUUN3ME2yOE4{ODl\|IN88US=>	MWjTRW5ITVJ?
MKN1	Mn3FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUTJR\|UxRTJ2Lk[4JO69VQ>?	NFThWXpUSU6JRWK=
MN-60	NWTRZ4NbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYfJR\|UxRTJ2Lki1NVkh\|ryP	Mmi1V2FPT0WU
8505C	M4DDe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYPHPFh1UUN3ME2yOU4yQDR3IN88US=>	MX7TRW5ITVJ?
COLO-320-HSR	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml;XTWM2OD1{NT6yNlA5KM7:TR?=	NH\ZN3BUSU6JRWK=
BB30-HNC	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXrpSldWUUN3ME2yOU4zPDh\|IN88US=>	M2Dj[3NCVkeHUh?=
KM12	MkfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUfJR\|UxRTJ3LkW4NFch\|ryP	MmLCV2FPT0WU
NB13	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1joVGlEPTB;MkWuOVg6QCEQvF2=	M13R[3NCVkeHUh?=
HCC2998	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUDJR\|UxRTJ4LkCyPFMh\|ryP	MlnVV2FPT0WU
U-118-MG	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3fmdGlEPTB;Mk[uNFgxQCEQvF2=	MYDTRW5ITVJ?
NB10	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlftTWM2OD1{Nj6yN\|Qh\|ryP	NG\UdVJUSU6JRWK=
SK-LMS-1	M3nkNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml[xTWM2OD1{Nz6wO\|A1KM7:TR?=	NV:4V2l4W0GQR1XS
SW1573	NWfYPW54T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHKxRXhKSzVyPUK3MlEyKM7:TR?=	MYrTRW5ITVJ?
LB373-MEL-D	NH\QXZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYn2VmQ2UUN3ME2yO{4yOjl2IN88US=>	NXy0dI05W0GQR1XS
DK-MG	NFi2WWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4Cz[WlEPTB;MkeuNVgyPyEQvF2=	MVTTRW5ITVJ?
RMG-I	M2DOSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVvJR\|UxRTJ5LkKwNlkh\|ryP	M3XVfHNCVkeHUh?=
SW1088	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXzJR\|UxRTJ5LkWwOFIh\|ryP	MYjTRW5ITVJ?
SK-OV-3	Ml;0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGDrcpZKSzVyPUK3Mlc2QTNizszN	NX:0[JNqW0GQR1XS
KP-N-YN	NWj4[ZBjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWn4PGFOUUN3ME2yO{45ODR\|IN88US=>	MkDZV2FPT0WU
RPMI-7951	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX;MWJcxUUN3ME2yPE4zPDV4IN88US=>	MmLEV2FPT0WU
CaR-1	NX\wc3JZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGnmc2dKSzVyPUK4MlU2QDJizszN	M3HDfHNCVkeHUh?=
MKN7	NILPT2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHmxTmdKSzVyPUK4MlU6PjRizszN	NVrId2VPW0GQR1XS
CHP-212	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXPnbYJrUUN3ME2yPE44PDBzIN88US=>	M3z3NHNCVkeHUh?=
KYSE-450	NHT2WG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIWzUW9KSzVyPUK4MlgxQTFizszN	M4PnXXNCVkeHUh?=
RXF393	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH:5VXBKSzVyPUK5MlI6ODZizszN	NHHpeIRUSU6JRWK=
P30-OHK	MoO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUX5fG56UUN3ME2yPU4{ODR6IN88US=>	MVXTRW5ITVJ?
Ca9-22	NUi4b4VrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYTJR\|UxRTJ7LkSyPVkh\|ryP	M4DkXnNCVkeHUh?=
RT-112	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkDBTWM2OD1{OT60OlEyKM7:TR?=	MVzTRW5ITVJ?
ES1	NGrI[oxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml3DTWM2OD1{OT64OVQ1KM7:TR?=	Mn\RV2FPT0WU
HCE-4	NVLiT3ROT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1LRfmlEPTB;MkmuPFc5PiEQvF2=	M2LGd3NCVkeHUh?=
AM-38	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1nt[2lEPTB;M{CuNFYxPiEQvF2=	MXTTRW5ITVJ?
AsPC-1	Mly4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkKwTWM2OD1\|MD64NFU{KM7:TR?=	NXjodpRHW0GQR1XS
TE-9	M1LXdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUjxO3ltUUN3ME2zNE45PzN5IN88US=>	NHPkfohUSU6JRWK=
HuP-T4	MlTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV\JR\|UxRTNyLkm2N\|gh\|ryP	M4PaUnNCVkeHUh?=
LB2518-MEL	M1PSXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmHQTWM2OD1\|MT6wO\|Q1KM7:TR?=	MYDTRW5ITVJ?
NCI-H1703	MkXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWLJR\|UxRTNzLkC5NFUh\|ryP	M1vxd3NCVkeHUh?=
NCI-H2228	M1PENGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXjJR\|UxRTNzLkS2OVEh\|ryP	MWDTRW5ITVJ?
SCC-4	M1T4S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFXCdHhKSzVyPUOxMlkyQDFizszN	MUfTRW5ITVJ?
KNS-81-FD	NHjaXG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{\LZ2lEPTB;M{KuNFEzQCEQvF2=	MY\TRW5ITVJ?
NTERA-S-cl-D1	NFLqW49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkHsTWM2OD1\|Mj6wO\|M6KM7:TR?=	MoTpV2FPT0WU
Daoy	NXzPfFhKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlnpTWM2OD1\|Mj6wPFM5KM7:TR?=	Mof6V2FPT0WU
ES4	MlzaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{TsSGlEPTB;M{KuN\|kzOiEQvF2=	NEfpZ45USU6JRWK=
MHH-ES-1	M2KzcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVTJR\|UxRTN{LkS4O\|Ih\|ryP	M1y4XHNCVkeHUh?=
C-33-A	NHLDd49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWjISGplUUN3ME2zNk44PzJ6IN88US=>	NYDucWo{W0GQR1XS
BHY	M1fEcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUHJR\|UxRTN{Lkm0PVUh\|ryP	NHHtRmJUSU6JRWK=
Detroit562	M{TwSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnLFTWM2OD1\|Mz62OlU4KM7:TR?=	NYq2OoRxW0GQR1XS
EW-1	MnP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NW[3cZd7UUN3ME2zN{46OzJ{IN88US=>	M3W4dHNCVkeHUh?=
NCI-H1395	NETlPFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUfJR\|UxRTN2LkC3PVkh\|ryP	NUS1S2VXW0GQR1XS
KM-H2	Mkn5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWDJR\|UxRTN4LkS3OFMh\|ryP	MUnTRW5ITVJ?
NCI-H520	NXPKfnNnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoizTWM2OD1\|Nj63OVQyKM7:TR?=	MVfTRW5ITVJ?
D-392MG	M3X1Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoHITWM2OD1\|Nz6zN\|Q1KM7:TR?=	NUDYZpdyW0GQR1XS
NOMO-1	M1ewUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGPGZpZKSzVyPUO3MlgxQDlizszN	NXXFZYNCW0GQR1XS
TE-6	NX7rdYdDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFfVUWhKSzVyPUO4MlEzPCEQvF2=	NUTBc3h[W0GQR1XS
HT-3	NWS5TnpJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3rQeWlEPTB;M{iuOFQ{PiEQvF2=	NXX2d5ZyW0GQR1XS
RPMI-8226	NFLuWHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlvYTWM2OD1\|OD65OVE6KM7:TR?=	NWP5bmlFW0GQR1XS
U251	M3K4SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M16xWGlEPTB;M{muNFEzPCEQvF2=	NHqxTpdUSU6JRWK=
GCT	NYP4eIVDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkfUTWM2OD1\|OT6xPFUzKM7:TR?=	MWnTRW5ITVJ?
A431	M4XPVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEDFTXVKSzVyPUO5MlE5QTRizszN	MWPTRW5ITVJ?
TE-12	MofXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmLVTWM2OD1\|OT6yOFQ5KM7:TR?=	MmnOV2FPT0WU
HMV-II	Mof3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVPJR\|UxRTN7LkWwOFch\|ryP	NHLPXlRUSU6JRWK=
IST-MES1	MkXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH\FdlNKSzVyPUSwMlE2ODJizszN	NXW1eJhnW0GQR1XS
SW13	M1voWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXrtXnhyUUN3ME20NE42OTlizszN	NFjUNW9USU6JRWK=
SF295	NHzuepBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4ewbWlEPTB;NECuPFA3PiEQvF2=	NGXmTXJUSU6JRWK=
MDA-MB-157	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoXZTWM2OD12MD65OFYzKM7:TR?=	NXKyb2RoW0GQR1XS
TE-1	NYDiTINrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWKyclF[UUN3ME20NU45PzF2IN88US=>	NVXaXHdRW0GQR1XS
HuCCT1	MmjXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mo\FTWM2OD12Mj61Nlg6KM7:TR?=	NFPFVGVUSU6JRWK=
KYSE-510	NVXFfVhYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUj1SFZ[UUN3ME20N{4yPzV2IN88US=>	NEjkcldUSU6JRWK=
NCI-H358	NU\E[GtDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1[2W2lEPTB;NESuNFMxPCEQvF2=	M1\KVnNCVkeHUh?=
SW900	M17QSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVLJR\|UxRTR2LkC3OVgh\|ryP	NEL2T3RUSU6JRWK=
CAS-1	Mn\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX7JR\|UxRTR2LkC5PVEh\|ryP	Mmm0V2FPT0WU
TE-8	NYnDemQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1fqWGlEPTB;NESuOVY2QCEQvF2=	M{nTPXNCVkeHUh?=
P12-ICHIKAWA	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYrJR\|UxRTR2Lk[xNVIh\|ryP	MmHzV2FPT0WU
YKG-1	NHzWPI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVzJR\|UxRTR2Lke4NUDPxE1?	NXjHW3J3W0GQR1XS
SNU-C2B	NWrhd3ZVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFPYbW1KSzVyPUS0Mlc6ODNizszN	NXjBc\|ZEW0GQR1XS
LCLC-103H	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUTJR\|UxRTR2Lki3NFMh\|ryP	MmSxV2FPT0WU
U-87-MG	M3PkRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX7VcG9kUUN3ME20OU4yODJ{IN88US=>	MVLTRW5ITVJ?
HAL-01	NYHZNGtiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF3pPVdKSzVyPUS1MlE{PzlizszN	NGG4RoVUSU6JRWK=
OVCAR-8	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVLTfVF4UUN3ME20OU4{PTZ2IN88US=>	M{KweXNCVkeHUh?=
KYSE-150	MlflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkX5TWM2OD12Nz6xNFUzKM7:TR?=	NU\B[\|BZW0GQR1XS
OE33	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUDJR\|UxRTR5LkG0Nlkh\|ryP	Moj4V2FPT0WU
CAL-62	NH;BOIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3PRRWlEPTB;NEeuOFA3QCEQvF2=	MVzTRW5ITVJ?
TCCSUP	M3TRVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MluyTWM2OD12Nz62NlY1KM7:TR?=	M1u3[3NCVkeHUh?=
H4	M2fCe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF;B[nVKSzVyPUS3MlY3OjFizszN	MofZV2FPT0WU
CP66-MEL	NYjWc496T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NI\ZeXhKSzVyPUS4MlA4ODRizszN	M4KweXNCVkeHUh?=
SNB75	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MU\JR\|UxRTR6LkG4O\|Qh\|ryP	MUTTRW5ITVJ?
Mo-T	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV3JR\|UxRTR6LkK3PUDPxE1?	MlPuV2FPT0WU
BT-549	NXfoSWdkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MW\JR\|UxRTR6LkO3Nlkh\|ryP	M1PafnNCVkeHUh?=
IGR-1	NULlNHV1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkHvTWM2OD12OD62OlQ2KM7:TR?=	M3;FOnNCVkeHUh?=
NCI-H1299	MlnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXjJR\|UxRTR6LkeyOFgh\|ryP	NXH1[m1RW0GQR1XS
ALL-PO	MkSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYjJR\|UxRTR7LkmyOlgh\|ryP	M{LmTHNCVkeHUh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-DNA-PKcs / DNA-PKcs / p-ATM / ATM / p-ATR / ATR / Ku70 / p-CHK1 / p-CHK2/ p-AKT / RAD51; PubMed: 29344644 Oncol Rep SUNE1 cells were irradiated with 5 Gy in the presence or absence of NU7441 (2 µM). The expression of cell cycle checkpoint proteins and double strand break repair proteins was assayed by western blot analysis at 6 or 12 h post-IR. p-mTOR(Ser2448) / mTOR / p-S6K(Thr389); PubMed: 25714019 Oncotarget Phosphorylation of mTOR and p70S6K were detected by Western blot analysis 24 hours after treatment.	29344644 25714019

In vivo

NU7441 intraperitoneally administrated at dose of 10 mg/kg maintains for at least 4 hours shows nontoxic and increases etoposide-induced tumor growth delay 2-fold in mice bearing SW620 xenografts. ^[2]

Protocol

Cell Research:

^[2]

- Collapse

Cell lines: SW620, LoVo, V3-YAC and V3 cells
Concentrations: 0.5 μM or 1 μM
Incubation Time: 17 hours
Method:
The effect of NU7441 on cellular survival following exposure to etoposide, doxorubicin, and ionizing radiation is measured in SW620, LoVo, V3, and V3-YAC cells by clonogenic assays. Briefly, growing cells in six-well plates or 6-cm dishes are exposed to etoposide or doxorubicin with or without NU7441 (0.5 or 1.0 μM) for 16 hours. For radiosensitization studies, NU7441 is added to the cells 1 hour before irradiation. V3 and V3-YAC cells are exposed to γ-irradiation (3.1 Gy/min ¹³⁷Cesium). SW620 and LoVo are exposed to X-irradiation (2.9 Gy/min at 230 kV, 10 mA) due to the equipment available. After irradiation, the cells are incubated with or without NU7441 for a further 16 hours. Cells are then harvested by trypsinization, counted, and seeded into 10-cm diameter Petri dishes at densities varying from 100 to 10⁵ per dish in drug-free medium for colony formation. Colonies are stained with crystal violet after 10 to 14 days and counted with an automated colony counter. The survival reduction factor (SRF) is calculated as the surviving fraction of cells in the absence of NU7441 divided by the surviving fraction of cells in the presence of NU7441 for any given dose or concentration of cytotoxic agent. The dose modification ratio (DMR90) is calculated as the concentration/dose of cytotoxic agent required to kill 90% of the cells in the absence of NU7441 divided by the concentration/dose of cytotoxic agent required to kill 90% of the cells in the presence of NU7441.

(Only for Reference)

Animal Research:

^[2]

- Collapse

Animal Models: Female rude mice bearing SW620 xenografts
Dosages: 10 mg/kg
Administration: Intraperitoneally administrated
(Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	4 mg/mL warmed (9.67 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	2mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download NU7441 (KU-57788) SDF

Molecular Weight	413.49
Formula	C₂₅H₁₉NO₃S
CAS No.	503468-95-9
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A
Smiles	O=C1C=C(OC2=C1C=CC=C2C3=CC=CC4=C3SC5=C4C=CC=C5)N6CCOCC6

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Could you please suggest formulations of the drug for in vivo injection?
Answer:
We tested the following formulation for in vivo use, 4% DMSO+30% PEG 300+5% Tween 80+ddH2O up to 1mg/mL. It is a clear solution.
Question 2:
Previous aliquots were clear and colorless while this time, it becomes yellow when the powder was dissolved in DMSO? Could you advice on this?
Answer:
Slight color variation due to different processing is normal and usually doesn't interfere with the function.

DNA-PK Signaling Pathway Map

DNA-PK Inhibitors with Unique Features

Non-specific DNA-PK Inhibitor

PI-103 : DNA-PK, IC50=23 nM; p110α/β/δ/γ, IC50=2 nM/3 nM/3 nM/15 nM; mTOR, IC50=30 nM.
Most Potent DNA-PK Inhibitor

PIK-75 : DNA-PK, IC50=2 nM.
Newest DNA-PK Inhibitor

KU-0060648 : Dual inhibitor of DNA-PK and PI3Kα, PI3Kβ, PI3Kδ with IC50 of 8.6 nM and 4 nM, 0.5 nM, 0.1 nM respectively, less inhibition of PI3Kγ with IC50 of 0.59 μM.
Classic DNA-PK Inhibitor

NU7026 : Potent DNA-PK inhibitor with IC50 of 0.23 μM, 60-fold selective for DNA-PK than PI3K and inactive against both ATM and ATR.

Related DNA-PK Products

CHIR-99021 (CT99021) ^New

CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively. CHIR99201 does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs.
Dorsomorphin (Compound C) ^New

Dorsomorphin is a potent, reversible, selective AMPK inhibitor with K_i of 109 nM in cell-free assays, exhibiting no significant inhibition of several structurally related kinases including ZAPK, SYK, PKCθ, PKA, and JAK3. Also inhibits type I BMP receptor activity.
MHY1485 ^New

MHY1485 is a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy.
NU7026

NU7026 is a potent DNA-PK inhibitor with IC50 of 0.23 μM in cell-free assays, 60-fold selective for DNA-PK than PI3K and inactive against both ATM and ATR.
KU-0060648

KU-0060648 is a dual inhibitor of DNA-PK and PI3Kα, PI3Kβ, PI3Kδ with IC50 of 8.6 nM and 4 nM, 0.5 nM, 0.1 nM respectively, less inhibition of PI3Kγ with IC50 of 0.59 μM.
Rapamycin (Sirolimus)

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
MK-2206 2HCl

MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.

Features:The first allosteric small molecule inhibitor of Akt to enter clinical development.
CHIR-99021 (CT99021) HCl

CHIR-99021 (CT99021) HCl is hydrochloride of CHIR-99021, which is a GSK-3α/β inhibitor with IC50 of 10 nM/6.7 nM; CHIR-99021 shows greater than 500-fold selectivity for GSK-3 versus its closest homologs Cdc2 and ERK2. CHIR-99021 is a potent pharmacological activators of the Wnt/beta-catenin signaling pathway. CHIR-99021 significantly rescues light-induced autophagy and augments GR, RORα and autophagy-related proteins.
LY294002

LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family.
3-Methyladenine (3-MA)

3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. Solutions of 3-MA are best fresh-prepared by heating.

Choose Your Country or Region

By Signaling Pathways

By product type

NU7441 (KU-57788)